Aytu BioPharma, Inc. AYTU
NASDAQ · United States · Health Technology
$2.07-0.02 (-0.96%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Moby summary of Aytu BioPharma, Inc.'s Q4 2026 earnings call
Aytu BioPharma Inc (AYTU) posted $16.1 million in Q4 FY2026 revenue as EXXUA prescriptions surged 138% and the company swung to positive adjusted EBITDA of $0.5 million.
Fourth quarter fiscal 2026 net revenue increased 6.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.